

## INDEX FOR THE SSI DISABILITY GUIDELINES

If a condition is not listed below, look in the disability guidelines beginning on the next page. NOTE: Eligibility may also be determined by reviewing the functional limitation of a condition or groups of conditions.

<u>Condition</u>	<u>Page</u>
ADHD.....	13
Amputation.....	1
Anemia (Hemolytic).....	7
Anxiety disorder.....	11-12
Arthritis (inflammatory).....	17
Asthma.....	3
Autism/PDD.....	13
Bowel disease (chronic inflammatory).....	6
Brain tumor (benign).....	9
Burns.....	7
Cancers/Tumors.....	13-14
Cerebral palsy.....	9
Communication impairment.....	10
Cystic fibrosis.....	3-4
Depression or Manic depression (mood disorders).....	10-11
Developmental & emotional disorders in infants.....	13
Diabetes (Mellitus & Insipidus).....	8
Digestive problems.....	5-6
Down syndrome.....	9
Dwarfism.....	8
Eating disorders.....	12
Endocrine problems.....	7-8
Epilepsy (Seizures).....	9
Fetal Alcohol Syndrome (see Multiple Body Systems).....	9
Fragile X Syndrome (see Multiple Body Systems).....	9
Growth impairment.....	1
Hearing loss.....	2
Heart problems.....	4
Hemophilia (Inherited Coagulation Disorder).....	7
HIV.....	16-17
Hypoglycemia.....	8
Immune deficiency disease (congenital).....	15-16
Kidney problems.....	6
Leukemia or Lymphoma.....	14
Liver disease.....	5
Low birth weight.....	1
Lung problems.....	2-4
Lupus Erythematosus (Systemic).....	14
Malnutrition.....	6
Mental health disorders.....	10-13
Mental retardation.....	11
Motor dysfunction.....	9
Multiple body systems.....	8-9
Musculoskeletal (joints, spine, amputations,fractures,etc.).....	1-2
Neuroblastoma or Retinablastoma.....	14
PKU (see Multiple Body Systems)	
Prematurity.....	1
Rheumatic fever.....	4
Sclerosis & Scleroderma (Systemic).....	15
Sickle cell disease.....	7
Skin disorders.....	7
Spina bifida (Meningomyelocele).....	9-10
Substance dependence disorder.....	12-13
Tic disorder.....	12
Thyroid problem.....	7-8
Turner's Syndrome.....	8
Vision Loss.....	2

## SSI MEDICAL EVALUATION GUIDELINES - Part B (children less than age 18 yrs.)

**This summary covers children less than age 18 years (called Part B).** In some instances, adult (age 18 & older) criteria are used for children. The website includes detailed explanations of the disability criteria. **Adult (age 18 & older) criteria, called Part A and the full Part B explanations can be found in the “Blue Book”, on the Social Security Website: [www.socialsecurity.gov/disability/professionals/bluebook](http://www.socialsecurity.gov/disability/professionals/bluebook)**

[Source: Disability Evaluation From Social Security “Blue Book” (as of January 4, 2010)]

### PREMATURITY & LOW BIRTH WEIGHT (25216.001)

**(Disability at least until the chronological age of 12 months) for 1 of the following:**

1. Infant weighing less than 1200 grams (about 2 lb. 10 oz.) at birth; OR
2. Infant weighing at least 1200 grams but less than 2000 grams (about 4 lb. 6 oz.) at birth AND is small for gestational age (birth weight  $\geq$  2 S.D. below the mean or  $<$  the 3<sup>rd</sup> percentile for gestational age).

### GROWTH IMPAIRMENT (100.00)

**Criteria are applicable only until closure of major epiphyses.** Determination of growth impairment should be based upon the comparison of current height with at least 3 previous determinations, including length at birth, if available.

- **RELATED to additional medical impairment (100.02) – Either a fall of greater than 15 percentiles in height which is sustained; or a fall to, or persistence of height below the 3rd percentile.**
- **NOT RELATED to additional medical impairment (100.03) - Both a fall of greater than 25 percentiles in height which is sustained; AND Bone age greater than 2 S.D. below the mean for chronological age.**

### MUSCULOSKELETAL (101.00)

<b>Major dysfunction of a joint(s), due to any cause</b> (101.02)	<b>Characterized by gross anatomical deformity</b> (e.g. subluxation, contracture, bony or fibrous ankylosis, instability) <b>and chronic joint pain and stiffness</b> with signs of limitation of motion or other abnormal motion of the affected joint(s), <b>and findings on appropriate medically acceptable imaging</b> of joint space narrowing, bony destruction, or ankylosis of the affected joint(s), with <b>EITHER A or B:</b> <b>A. Involvement of one major peripheral weight-bearing joint</b> (i.e. hip, knee, or ankle), resulting in inability to ambulate effectively; or <b>B. Involvement of one major peripheral joint in each upper extremity</b> (i.e. shoulder, elbow, or wrist-hand), resulting in ability to perform fine and gross movements effectively.
<b>Reconstructive surgery or surgical arthrodesis</b> (101.03)	<b>Of a major weight-bearing joint</b> , with inability to ambulate effectively, and return to effective ambulation didn't occur, or is not expected to occur, within 12 months of onset.
<b>Disorders of the spine</b> (101.04)	(e.g., lysosomal disorders, metabolic disorders, vertebral osteomyelitis, vertebral fracture, achondroplasia): Resulting in compromise of a nerve root (including the cauda equina) or the spinal cord, with evidence of nerve root compression characterized by neuro-anatomic distribution of pain, limitation of motion of the spine, motor loss (atrophy with associated muscle weakness) accompanied by sensory or reflex loss & , if there is involvement of the lower back, positive straight-leg raising test (sitting & supine).
<b>Amputation (due to any cause)</b> (101.05)	<b>With 1 of the following:</b> <b>A. Both hands; OR</b> <b>B. One or both lower extremities at or above the tarsal region, with stump complications</b> resulting in medical inability to use a prosthetic device to ambulate effectively, which have lasted or are expected to last for at least 12 months; <b>OR</b> <b>C. Hemipelvectomy or hip disarticulation; OR</b> <b>D. One hand &amp; one lower extremity at or above tarsal region</b> , with inability to ambulate effectively.
<b>Fracture(s) (femur, tibia, pelvis, <math>\geq</math> 1 tarsal)</b> (101.06)	<b>Fractures of femur, tibia, pelvis, or one or more tarsal bones, with BOTH of the following:</b> <b>A. Solid union not evident</b> on appropriate medically acceptable imaging, and not clinically solid; <b>AND</b> <b>B. Inability to ambulate effectively</b> , and return to effective ambulation did not occur or is not expected to occur within 12 months of onset.
<b>Upper extremity fracture</b> (101.07)	<b>With nonunion of a fracture of the shaft of the humerus, radius, or ulna</b> , under continuing surgical management, directed toward restoration of functional use of the extremity, and such function was not restored or expected to be restored within 12 months of onset.

<b>Soft tissue injury</b> (101.08)	(e.g. burns) of an upper or lower extremity, trunk, or face and head, under continuing surgical management, directed toward the salvage or restoration of major function, and such major function was not restored or expected to be restored within 12 months of onset.																											
<b>SPECIAL SENSES and SPEECH (102.00)</b>																												
<b>Loss of visual acuity</b> (102.02)	<p><b>With 1 of the following:</b></p> <p><b>A. Remaining vision in better eye</b> after best correction is 20/200 or less; <b>OR</b></p> <p><b>B. Inability to participate in testing using Snellen methodology or other comparable visual acuity testing</b> &amp; clinical findings that fixation &amp; visual-following behavior are absent in the better eye, <b>and 1 of the following:</b></p> <ol style="list-style-type: none"> <li>1. Abnormal anatomical findings indicating a visual acuity of 20/200 or less in the better eye; or</li> <li>2. Abnormal neuroimaging documenting damage to the cerebral cortex which would be expected to prevent the development of a visual acuity better than 20/200 in the better eye; or</li> <li>3. Abnormal electroretinogram documenting the presence of Leber's congenital amaurosis or achromatopsia; or</li> <li>4. An absent response to VER testing in the better eye</li> </ol>																											
<b>Visual field in the better eye</b> (102.03)	<p><b>Loss of visual field in the better eye, with 1 of the following:</b></p> <p><b>A. The widest diameter subtending an angle around the point of fixation</b> no &gt; 20 degrees; <b>OR</b></p> <p><b>B. A mean deviation</b> of -22 or worse, determined by automated static threshold perimetry; <b>OR</b></p> <p><b>C. A visual field efficiency</b> of 20 percent or less as determined by kinetic perimetry.</p>																											
<b>Visual efficiency</b> (102.04)	<b>Loss of visual efficiency – visual efficiency of the better eye of 20 percent or less</b> after best correction																											
<b>Hearing – Not treated with cochlear implant</b> (102.10); <b>OR</b> <b>Treated with cochlear implant</b> (102.11)	<p>(Select appropriate age group, based on age at the time of decision):</p> <p><b>A. Birth to age 5 years: NOT treated with cochlear implant</b> - Average air conduction hearing threshold <math>\geq 50</math> decibels in the better ear. <b>OR TREATED with implant</b> – Considered a disability until age 5 or for 1 yr after initial implantation, whichever is later.</p> <p><b>B. Age 5 years to 18 years and NOT treated with cochlear implant - 1 of the following:</b></p> <ol style="list-style-type: none"> <li>1. <b>Average air conduction hearing threshold</b> of <math>\geq 70</math> db in better ear and an average bone conduction hearing threshold <math>\geq 40</math> decibels in the better ear; <b>OR</b> average air conduction hearing threshold <math>\geq 50</math> db in better ear, &amp; marked limitation in speech or language; <b>OR</b></li> <li>2. <b>Word recognition score</b> <math>\leq 40\%</math> in better ear determined using a standardized list of phonetically balanced monosyllabic words.</li> </ol> <p><b>Age 5 yrs to 18yrs. and TREATED with implant</b> – Age 5 years or 1 year after initial implantation, whichever is later, a word recognition score of 60% or less determined using the HINT or HINT-C.</p>																											
<b>RESPIRATORY (103.00)</b>																												
<b>Chronic pulmonary insufficiency</b> (103.02)	<p><b>With 1 of the following:</b></p> <p><b>A. Chronic obstructive pulmonary disease</b> due to any cause with <math>FEV_1 \leq</math> value in <b>Table I</b> (below); <b>OR</b></p> <p><b>B. Chronic restrictive ventilatory disease</b>, due to any cause, with <math>FVC \leq</math> value in <b>Table II</b> (below); <b>OR</b></p> <p><b>C. Frequent need for 1 of the following:</b></p> <ol style="list-style-type: none"> <li>1. Mechanical ventilation; or</li> <li>2. Nocturnal supplemental oxygen as required by persistent or recurrent hypoxemia; <b>OR</b></li> </ol> <p><b>D. Presence of a tracheostomy</b> in a child less than 3 years old; <b>OR</b></p> <table border="0" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th style="text-align: center;">Height Without Shoes (cm/inches)</th> <th style="text-align: center;">TABLE I <math>FEV_1 \leq</math></th> <th style="text-align: center;">TABLE II <math>FVC_1 \leq</math></th> </tr> </thead> <tbody> <tr> <td style="text-align: center;"><math>\leq 119 / \leq 46</math></td> <td style="text-align: center;"><b>0.65</b></td> <td style="text-align: center;"><b>0.65</b></td> </tr> <tr> <td style="text-align: center;"><b>120-129/47-50</b></td> <td style="text-align: center;"><b>0.75</b></td> <td style="text-align: center;"><b>0.85</b></td> </tr> <tr> <td style="text-align: center;"><b>130-139/51-54</b></td> <td style="text-align: center;"><b>0.95</b></td> <td style="text-align: center;"><b>1.05</b></td> </tr> <tr> <td style="text-align: center;"><b>140-149/55-58</b></td> <td style="text-align: center;"><b>1.15</b></td> <td style="text-align: center;"><b>1.25</b></td> </tr> <tr> <td style="text-align: center;"><b>150-159/59-62</b></td> <td style="text-align: center;"><b>1.35</b></td> <td style="text-align: center;"><b>1.45</b></td> </tr> <tr> <td style="text-align: center;"><b>160-164/63-64</b></td> <td style="text-align: center;"><b>1.45</b></td> <td style="text-align: center;"><b>1.65</b></td> </tr> <tr> <td style="text-align: center;"><b>165-169/65-66</b></td> <td style="text-align: center;"><b>1.55</b></td> <td style="text-align: center;"><b>1.75</b></td> </tr> <tr> <td style="text-align: center;"><math>\geq 170 / \geq 67</math></td> <td style="text-align: center;"><b>1.65</b></td> <td style="text-align: center;"><b>2.05</b> <b>OR</b> (continued next page)</td> </tr> </tbody> </table>	Height Without Shoes (cm/inches)	TABLE I $FEV_1 \leq$	TABLE II $FVC_1 \leq$	$\leq 119 / \leq 46$	<b>0.65</b>	<b>0.65</b>	<b>120-129/47-50</b>	<b>0.75</b>	<b>0.85</b>	<b>130-139/51-54</b>	<b>0.95</b>	<b>1.05</b>	<b>140-149/55-58</b>	<b>1.15</b>	<b>1.25</b>	<b>150-159/59-62</b>	<b>1.35</b>	<b>1.45</b>	<b>160-164/63-64</b>	<b>1.45</b>	<b>1.65</b>	<b>165-169/65-66</b>	<b>1.55</b>	<b>1.75</b>	$\geq 170 / \geq 67$	<b>1.65</b>	<b>2.05</b> <b>OR</b> (continued next page)
Height Without Shoes (cm/inches)	TABLE I $FEV_1 \leq$	TABLE II $FVC_1 \leq$																										
$\leq 119 / \leq 46$	<b>0.65</b>	<b>0.65</b>																										
<b>120-129/47-50</b>	<b>0.75</b>	<b>0.85</b>																										
<b>130-139/51-54</b>	<b>0.95</b>	<b>1.05</b>																										
<b>140-149/55-58</b>	<b>1.15</b>	<b>1.25</b>																										
<b>150-159/59-62</b>	<b>1.35</b>	<b>1.45</b>																										
<b>160-164/63-64</b>	<b>1.45</b>	<b>1.65</b>																										
<b>165-169/65-66</b>	<b>1.55</b>	<b>1.75</b>																										
$\geq 170 / \geq 67$	<b>1.65</b>	<b>2.05</b> <b>OR</b> (continued next page)																										

<p><b>Chronic pulmonary insufficiency</b> (103.02)</p> <p>Continued</p>	<p><b>E. Bronchopulmonary dysplasia</b>, characterized by <b>2 of the following</b>:</p> <ol style="list-style-type: none"> <li>1. Prolonged expirations; or</li> <li>2. Retractions, flaring and tachypnea indicating intermittent wheezing or increased respiratory effort; or</li> <li>3. Hyperinflation and scarring on chest x-ray or other appropriate imaging technique; or</li> <li>4. Bronchodilator or diuretic dependence; or</li> <li>5. Frequent requirement for nocturnal supplemental oxygen; or</li> <li>6. Weight disturbance persisting for <math>\geq 2</math> months, with an involuntary weight loss (or failure to gain weight at an appropriate rate of age) resulting in a fall from the established growth curve of either 15 percentiles or to below the 3<sup>rd</sup> percentile; <b>OR</b></li> </ol> <p><b>F. 2 required hospital admissions</b> (each longer than 24 hr.) within a 6-month period for recurrent lower respiratory tract infections or acute respiratory distress associated <b>with either</b>:</p> <ol style="list-style-type: none"> <li>1. chronic wheezing or chronic respiratory distress; or</li> <li>2. weight disturbance (as described above under Bronchopulmonary Dysplasia weight disturbance); <b>OR</b></li> </ol> <p><b>G. Chronic hypoventilation</b> (<math>\text{PaCO}_2 &gt; 45</math> mm Hg) <b>or chronic cor pulmonale</b> (see Chronic Heart Failure 104.02); <b>OR</b></p> <p><b>H. Growth impairment (100.00).</b></p>																				
<p><b>Asthma</b> (103.03)</p>	<p><b>With 1 of the following</b>:</p> <p><b>A.</b> <math>\text{FEV}_1 \leq</math> value specified in Table I (see 103.02 on page 2); <b>OR</b></p> <p><b>B. Attacks in spite of prescribed treatment &amp; requiring physician intervention, occurring at least once every 2 months or at least 6 times/year.</b> Each inpatient hospitalization for longer than 24 hr for control of asthma counts as 2 attacks, &amp; an evaluation period of at least 12 consecutive months must be used to determine the frequency of attacks. (Attacks are defined as prolonged symptomatic episodes lasting 1 day &amp; requiring intensive treatment, such as IV bronchodilator or antibiotic or prolonged inhalation therapy in a hospital, or equivalent setting.) <b>OR</b></p> <p><b>C. Growth impairment (100.00); OR</b></p> <p><b>D. Persistent low-grade wheezing between attacks or absence of extended symptom-free periods</b> requiring daytime and nocturnal use of sympathomimetic bronchodilators <b>with 1 of the following</b>:</p> <ol style="list-style-type: none"> <li>1. Persistent prolonged expiration with x-ray or other appropriate imaging techniques evidence of pulmonary hyperinflation or peribronchial disease; or</li> <li>2. Short courses of corticosteroids; average <math>&gt; 5</math> days/mo. for at least 3 mo., during a 12-mo. period.</li> </ol>																				
<p><b>Cystic fibrosis</b> (103.04)</p>	<p><b>With 1 of the following</b>:</p> <p><b>A.</b> <math>\text{FEV}_1 \leq</math> values in Table III</p> <table border="1" data-bbox="467 1255 1026 1621" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th colspan="2" style="text-align: center;">TABLE III</th> </tr> <tr> <th style="text-align: center;">Height Without Shoes (cm/inches)</th> <th style="text-align: center;"><math>\text{FEV}_1 \leq</math></th> </tr> </thead> <tbody> <tr> <td style="text-align: center;"><math>\leq 119/\leq 46</math></td> <td style="text-align: center;"><b>0.75</b></td> </tr> <tr> <td style="text-align: center;"><b>120-129/47-50</b></td> <td style="text-align: center;"><b>0.85</b></td> </tr> <tr> <td style="text-align: center;"><b>130-139/51-54</b></td> <td style="text-align: center;"><b>1.05</b></td> </tr> <tr> <td style="text-align: center;"><b>140-149/55-58</b></td> <td style="text-align: center;"><b>1.35</b></td> </tr> <tr> <td style="text-align: center;"><b>150-159/59-62</b></td> <td style="text-align: center;"><b>1.55</b></td> </tr> <tr> <td style="text-align: center;"><b>160-164/63-64</b></td> <td style="text-align: center;"><b>1.85</b></td> </tr> <tr> <td style="text-align: center;"><b>165-169/65-66</b></td> <td style="text-align: center;"><b>2.05</b></td> </tr> <tr> <td style="text-align: center;"><math>\geq 170/67</math></td> <td style="text-align: center;"><b>2.25    OR</b></td> </tr> </tbody> </table> <p><b>B. For Child unable to perform ventilatory function testing - 2 of the following</b>:</p> <ol style="list-style-type: none"> <li>1. History of dyspnea on exertion or accumulation of secretions as manifested by repetitive coughing or cyanosis; or</li> <li>2. Persistent bilateral rales and rhonchi or substantial reduction of breath sounds related to mucus plugging of trachea or bronchi; or</li> <li>3. Appropriate medically acceptable evidence of extensive disease, such as thickening of proximal bronchial airways or persistence of bilateral peribronchial infiltration; <b>OR</b></li> </ol>	TABLE III		Height Without Shoes (cm/inches)	$\text{FEV}_1 \leq$	$\leq 119/\leq 46$	<b>0.75</b>	<b>120-129/47-50</b>	<b>0.85</b>	<b>130-139/51-54</b>	<b>1.05</b>	<b>140-149/55-58</b>	<b>1.35</b>	<b>150-159/59-62</b>	<b>1.55</b>	<b>160-164/63-64</b>	<b>1.85</b>	<b>165-169/65-66</b>	<b>2.05</b>	$\geq 170/67$	<b>2.25    OR</b>
TABLE III																					
Height Without Shoes (cm/inches)	$\text{FEV}_1 \leq$																				
$\leq 119/\leq 46$	<b>0.75</b>																				
<b>120-129/47-50</b>	<b>0.85</b>																				
<b>130-139/51-54</b>	<b>1.05</b>																				
<b>140-149/55-58</b>	<b>1.35</b>																				
<b>150-159/59-62</b>	<b>1.55</b>																				
<b>160-164/63-64</b>	<b>1.85</b>																				
<b>165-169/65-66</b>	<b>2.05</b>																				
$\geq 170/67$	<b>2.25    OR</b>																				

<b>Cystic fibrosis</b> (103.04) continued	<p><b>C. Persistent pulmonary infection</b> accompanied by superimposed, recurrent, symptomatic episodes of increased bacterial infection occurring at least once every 6 months and requiring intravenous or nebulization antimicrobial treatment; <b>OR</b></p> <p><b>D. Episodes of bronchitis or pneumonia or hemoptysis (more than blood-streaked sputum) or respiratory failure</b>, requiring physician intervention, occurring once every 2 mo. or 6 times/yr. Each inpatient hospitalization for longer than 24 hours for treatment counts as 2 episodes, and an evaluation period of at least 12 consecutive months must be used to determine frequency of episodes; <b>OR</b></p> <p><b>E. Growth impairment (100.00).</b></p>																												
<b>Lung transplant</b> (103.05)	<p><b>Consider under a disability for 12 months following the date of surgery;</b> thereafter, evaluate the residual impairment(s)</p>																												
<b>CARDIOVASCULAR (104.00)</b>																													
<b>Chronic heart failure</b> (104.02)	<p><b>While on a regime of prescribed treatment, but still have 1 of the following:</b></p> <p><b>A. Persistent tachycardia at rest</b> (see Table I); <b>OR</b></p> <p><b>B. Persistent tachypnea at rest</b> (see Table II); <b>or markedly decreased exercise tolerance; OR</b></p> <p><b>C. Growth disturbance</b> with involuntary wt. loss or failure to gain wt. at appropriate rate for age, with either a fall of 15 percentiles or a fall to below the 3<sup>rd</sup> percentile (persisting for 2 months).</p> <table border="0" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2" style="text-align: left; border-bottom: 1px solid black;">TABLE I-TACHYCARDIA AT REST</th> <th colspan="2" style="text-align: right; border-bottom: 1px solid black;">TABLE II-TACHYPNEA AT REST</th> </tr> <tr> <th style="text-align: left;">Age</th> <th style="text-align: left;">(apical heart beats/minute)</th> <th style="text-align: left;">Age</th> <th style="text-align: left;">(respiratory rate per minute over)</th> </tr> </thead> <tbody> <tr> <td>Under 1 year</td> <td style="text-align: right;">150</td> <td>Under 1 year</td> <td style="text-align: right;">40</td> </tr> <tr> <td>1 through 3 years</td> <td style="text-align: right;">130</td> <td>1 through 5 years</td> <td style="text-align: right;">35</td> </tr> <tr> <td>4 through 9 years</td> <td style="text-align: right;">120</td> <td>6 through 9 years</td> <td style="text-align: right;">30</td> </tr> <tr> <td>10 through 15 years</td> <td style="text-align: right;">110</td> <td>Over 9 years</td> <td style="text-align: right;">25</td> </tr> <tr> <td>Over 15 years</td> <td style="text-align: right;">100</td> <td></td> <td></td> </tr> </tbody> </table>	TABLE I-TACHYCARDIA AT REST		TABLE II-TACHYPNEA AT REST		Age	(apical heart beats/minute)	Age	(respiratory rate per minute over)	Under 1 year	150	Under 1 year	40	1 through 3 years	130	1 through 5 years	35	4 through 9 years	120	6 through 9 years	30	10 through 15 years	110	Over 9 years	25	Over 15 years	100		
TABLE I-TACHYCARDIA AT REST		TABLE II-TACHYPNEA AT REST																											
Age	(apical heart beats/minute)	Age	(respiratory rate per minute over)																										
Under 1 year	150	Under 1 year	40																										
1 through 3 years	130	1 through 5 years	35																										
4 through 9 years	120	6 through 9 years	30																										
10 through 15 years	110	Over 9 years	25																										
Over 15 years	100																												
<b>Recurrent Arrhythmias</b> (104.05)	<p><b>Not related to reversible causes</b> such as electrolyte abnormalities or digitalis glycoside or antiarrhythmic drug toxicity, resulting in uncontrolled, recurrent episodes of cardiac syncope or near syncope, despite prescribed treatment, and documented by resting or ambulatory (Holter) electrocardiography, or by other appropriate medically acceptable testing, coincident with the occurrence of syncope or near syncope.</p>																												
<b>Congenital heart disease</b> (104.06)	<p><b>With 1 of the following:</b></p> <p><b>A. Cyanotic heart disease</b>, with persistent chronic hypoxemia, as manifested <b>by 1 of the following:</b></p> <ol style="list-style-type: none"> <li>1. Hematocrit 55% or greater on 2 evaluations. 3 or more months apart within a consecutive 12-month period; or</li> <li>2. Arterial O<sub>2</sub> saturation of less than 90% in room air, or resting PO<sub>2</sub> of 60 Torr or less; or</li> <li>3. Hypercyanotic spells, syncope, characteristic squatting, or other incapacitating symptoms directly related to documented cyanotic heart disease; or</li> <li>4. Exercise intolerance with increased hypoxemia on exertion; <b>OR</b></li> </ol> <p><b>B. Secondary pulmonary vascular obstructive disease</b> with a mean pulmonary arterial systolic pressure elevated to at least 70% of the systemic arterial systolic pressure; <b>OR</b></p> <p><b>C. Symptomatic acyanotic heart disease</b>, with ventricular dysfunction interfering very seriously with the ability to independently initiate, sustain, or complete activities; <b>OR</b></p> <p><b>D. For infants over 12 months of age at the time of filing</b>, with life-threatening congenital heart impairment that will require or already has required surgical treatment in first year of life, and the impairment is expected to be disabling (because of residual impairment following surgery, or the recovery time required, or both) until the attainment of at least 1 yr. of age. Infant considered disabled until attainment of at least age 1; thereafter, evaluate impairment severity with reference to the appropriate listing.</p>																												
<b>Heart Transplant</b> (104.09)	<p><b>Consider under a disability for 1 year following surgery;</b> thereafter, evaluate residual impairment under the appropriate listing.</p>																												
<b>Rheumatic heart disease</b> (104.13)	<p><b>With persistence of rheumatic fever activity with</b> significant murmur(s), cardiac enlargement or ventricular dysfunction, &amp; other associated abnormal lab findings (ex: elevated sedimentation rate or ECG findings) for 6 mo. or more (within 12-mo. period). Disabled for 18 mo. then evaluate residual impairment</p>																												

**DIGESTIVE (105.00)**

<b>Gastrointestinal Hemorrhaging</b> (105.02)	<b>Gastrointestinal hemorrhaging from any cause</b> , requiring blood transfusion (with or without hospitalization) of at least 10 cc of blood/kg of body weight, & occurring at least 3 times during a consecutive 6-month period. Transfusions must be at least 30 days apart within the 6-month period. Consider a disability for 1 year following last documented transfusion; thereafter, evaluate the residual impairment(s).
<b>Chronic Liver Disease</b> (105.05)	<b>With 1 of the following:</b> <b>A. Hemorrhaging from esophageal, gastric, or ectopic varices or from portal hypertensive gastropathy</b> , demonstrated by endoscopy, x-ray, or other appropriate medically acceptable imaging, resulting in hemodynamic instability, & requiring hospitalization for transfusion of at least 10 cc of blood/kg of body wt. Consider a disability for 1 year following last documented transfusion; thereafter, evaluate the residual impairment(s); <b>OR</b> <b>B. Ascites or hydrothorax</b> not attributable to other causes, despite continuing treatment as prescribed, present on at least 2 evaluations at least 60 days apart within a consecutive 6-month period; <b>each evaluation documented by 1 of the following:</b> <ol style="list-style-type: none"><li>1. Paracentesis or thoracentesis; or</li><li>2. Appropriate medically acceptable imaging or physical exam and <b>1 of the following</b><ol style="list-style-type: none"><li>a) Serum albumin of 3.0 g/dL or less; or</li><li>b) International Normalized Ratio (INR) of at least 1.5; <b>OR</b></li></ol></li></ol> <b>C. Spontaneous bacterial peritonitis</b> with peritoneal fluid containing an absolute neutrophil count of at least 250 cells/mm <sup>3</sup> ; <b>OR</b> <b>D. Hepatorenal syndrome, with 1 of the following:</b> <ol style="list-style-type: none"><li>1. Serum creatinine elevation of at least 2 mg/dL; or</li><li>2. Oliguria with 24-hr. urine output less than 1 mL/kg/hr; or</li><li>3. Sodium retention with urine sodium less than 10 mEq per liter;<b>OR</b></li></ol> <b>E. Hepatopulmonary syndrome , with 1 of the following:</b> <ol style="list-style-type: none"><li>1. Arterial oxygenation (P<sub>a</sub>O<sub>2</sub>) on room air of <b>1 of the following:</b><ol style="list-style-type: none"><li>a) 60 mm Hg or less, at tests sites less than 3,000 ft. above sea level, or</li><li>b) 55 mm Hg or less, at test sites from 3,000 to 6,000 ft. above sea level, or</li><li>c) 50 mm Hg or less, at test sites above 6,000 ft.; <b>OR</b></li></ol></li><li>2. Documentation of intrapulmonary arteriovenous shunting by contrast-enhanced echocardiography or macroaggregated albumin lung perfusion scan. <b>OR</b></li></ol> <b>F. Hepatic encephalopathy, WITH #1 below AND EITHER # 2 or # 3 below:</b> <ol style="list-style-type: none"><li>1. Documentation <b>of abnormal behavior, cognitive dysfunction, changes in mental status, or altered state of consciousness</b> (for ex: confusion, delirium, stupor, or coma), present on at least 2 evaluations at least 60 days apart within a consecutive 6-month period; <b>AND</b></li><li>2. History of transjugular intrahepatic portosystemic shunt (<b>TIPS</b>) or any surgical portosystemic shunt; or</li><li>3. <b>1 of the following</b> occurring on at least 2 evaluations at least 60 days apart within the same consecutive 6-month period as in Hepatic encephalopathy #1 above (under Hepatic encephalopathy):<ol style="list-style-type: none"><li>a) Asterixis or other fluctuating physical neurological abnormalities; or</li><li>b) Electroencephalogram (EEG) demonstrating triphasic slow wave activity; or</li><li>c) Serum albumin of 3.0 g/dL or less; or</li><li>d) International Normalized Ratio (INR) of 1.5 or greater. <b>OR</b></li></ol></li></ol> <b>G. End Stage Liver Disease, with</b> (select appropriate age group): <b>For children 12 years or older</b> , SSA CLD scores of 22 or greater. Consider a disability from at least the date of the first score. <b>For children under age 12years</b> , SSA CLD-P scores of 11 or greater. Consider under a disability from at least the date of the first score. <b>H. Extrahepatic biliary atresia as diagnosed on liver biopsy or intraoperative cholangiogram.</b> Consider disabled for 1 year following the diagnosis; thereafter, evaluate the residual liver function.

<b>Inflammatory bowel disease (IBD)</b> (105.06)	<p><b>Documented by endoscopy, biopsy, appropriate medically acceptable imaging, or operative findings, with 1 of the following:</b></p> <p><b>A. Obstruction of stenotic areas</b> (not adhesions) in the small intestine or colon with proximal dilation, confirmed by appropriate medically acceptable imaging or in surgery, requiring hospitalization of intestinal decompression or for surgery, and occurring on at least 2 occasions at least 60 days apart within a consecutive 6-month period; <b>OR</b></p> <p><b>B. 2 of the following</b>, despite continuing treatment as prescribed and occurring within the same consecutive 6 month period:</p> <ol style="list-style-type: none"> <li>1. Anemia with hemoglobin less than 10.0 g/dL, present on at least 2 evaluations at least 60 days apart; or</li> <li>2. Serum albumin of 3.0 g/dL or less, present on at least 2 evaluations at least 60 days apart; OR</li> <li>3. Clinically documented tender abdominal mass palpable on physical exam with abdominal pain or cramping that is not completely controlled by prescribed narcotic medication, present on at least 2 evaluations at least 60 days apart; or</li> <li>4. Perineal disease with a draining abscess or fistula, with pain that is not completely controlled by prescribed narcotic medication, present on at least 2 evaluations at least 60 days part; or</li> <li>5. Need for supplemental daily enteral nutrition via a gastrostomy or daily parenteral nutrition via a central venous catheter (See 105.10 for children under age 3 years.)</li> </ol>
<b>Short bowel syndrome</b> (105.07)	<p><b>Due to surgical resection of more than one-half of the small intestine</b>, with dependence on daily parenteral nutrition via a central venous catheter</p>
<b>Malnutrition</b> (105.08)	<p><b>Due to any digestive disorder, with BOTH of the following:</b></p> <p><b>A. Chronic nutritional deficiency</b> despite continuing treatment as prescribed, present on at least 2 evaluations at least 60 days apart within a consecutive 6-month period, <b>and documented by 1 of the following:</b></p> <ol style="list-style-type: none"> <li>1. Anemia with hemoglobin less than 10.0 g/dL; or</li> <li>2. Serum albumin of 3.0 g/dL or less; or</li> <li>3. Fat-soluble vitamin, mineral, or trace mineral deficiency; <b>AND</b></li> </ol> <p><b>B. Growth retardation</b> documented by (select appropriate age group):</p> <p><b>For children under age 2 years:</b> Multiple weight-for-length measurements that are less than the 3<sup>rd</sup> percentile, documented at least 3 times within a consecutive 6-month period; or</p> <p><b>For children age 2 and older:</b> Multiple Body Mass Index (BMI)-for age-measurements that are less than the 3<sup>rd</sup> percentile, documented at least 3 times within a consecutive 6-month period.</p>
<b>Liver Transplant</b> (105.09)	<p>Consider a disability for 1 yr. following the date of transplantation; thereafter, evaluate the residual impairment(s).</p>
<b>Gastrostomy Feedings</b> (105.10)	<p><b>Need for supplemental daily enteral feeding</b> via a gastrostomy due to any cause, for children who have not attained age 3 years; evaluate the residual impairment(s).</p>
<b>GENITO-URINARY (106.00)</b>	
<b>Impairment of renal function</b> (106.02)	<p><b>Due to any chronic renal disease</b> that has lasted or can be expected to last for a continuous period of at least 12 months; <b>with 1 of the following:</b></p> <p><b>A. Chronic hemodialysis or peritoneal dialysis; OR</b></p> <p><b>B. Kidney transplant</b> (consider a disability for 12 months following surgery; thereafter, evaluate the residual impairment); <b>OR</b></p> <p><b>C. Persistent elevation of serum creatinine</b> to greater than or equal to 3 mg/dL, over at least 3 months; <b>OR</b></p> <p><b>D. Reduction of creatinine clearance</b> to 30 ml per minute (43 liters/24hr) per 1.73 m<sup>2</sup> of body surface area over at least 3 months.</p>
<b>Nephrotic syndrome</b> (106.06)	<p><b>With anasarca (edema), persisting at least 3 mo, despite prescribed therapy; with 1 of the following:</b></p> <p><b>A. Serum albumin</b> less than or equal to 2.0 g/dL (100 ml); <b>OR</b></p> <p><b>B. Proteinuria</b> greater than or equal to 40 mg/m<sup>2</sup>/hr.</p> <p>(May also evaluate complications of the nephrotic syndrome, such as orthostatic hypotension, recurrent infections, or venous thromboses, under the appropriate listing for the resultant impairment.)</p>

<b>Congenital Genito-urinary</b> (106.07)	<b>Resulting in 1 of the following</b> occurring at least 3 times in a consecutive 12-month period: A. Repeated <b>urologic surgical procedures</b> ; OR B. Documented episodes of <b>systemic infection</b> requiring an initial course of parenteral antibiotics; OR C. Hospitalization for episodes of <b>electrolyte disturbance</b> .
<b>HEMATOLOGICAL (107.00)</b>	
<b>Hemolytic anemia</b> (107.03)	<b>Due to any cause</b> and manifested by persistent hematocrit less than or equal to 26 percent despite prescribed therapy, and reticulocyte count of 4 percent or greater.
<b>Sickle cell disease</b> (107.05)	<b>With 1 of the following:</b> A. Recent, recurrent severe <b>vaso-occlusive crises</b> (musculoskeletal, vertebral, abdominal); <b>OR</b> B. Major <b>visceral complication</b> in 12 months prior to application; <b>OR</b> C. <b>Hyperhemolytic or aplastic crisis</b> within 12 months prior to application; <b>OR</b> D. Chronic, severe <b>anemia</b> with persistent hematocrit of 26 percent or less; <b>OR</b> E. <b>Congestive heart failure</b> (104.02), <b>cerebrovascular damage</b> (111.00), or <b>emotional disorder</b> (112.00).
<b>Thrombocytopenia purpura of childhood</b> (107.06)	<b>Chronic idiopathic thrombocytopenia purpura of childhood</b> , with purpura and thrombocytopenia of less than or equal to 40,000 platelets/cu mm despite prescribed therapy or recurrent upon withdrawal of treatment.
<b>Inherited coagulation</b> (107.08)	<b>Inherited coagulation disorder, with EITHER:</b> A. Repeated spontaneous or inappropriate <b>bleeding</b> ; <b>OR</b> B. <b>Hemarthrosis</b> with joint deformity.
<b>SKIN CONDITIONS (108.00)</b>	
<b>Ichthyosis</b> (108.02)	<b>With extensive skin lesions</b> that persist for at least 3 months despite continuing treatment as prescribed.
<b>Bullous disease</b> (108.03)	( <b>Ex: pemphigus, erythema multiforme bullosum, epidermolysis bullosa, bullous pemphigoid, dermatitis herpetiformis</b> ), with extensive lesions skin lesions persisting at least 3 months despite continuing prescribed treatment.
<b>Skin or mucous membrane infections</b> (108.04)	<b>Chronic</b> infections with extensive fungating, or extensive ulcerating skin lesions that persist for at least 3 months despite continuing treatment as prescribed.
<b>Dermatitis</b> (108.05)	( <b>Ex: psoriasis, dyshidrosis, atopic dermatitis, exfoliative dermatitis, allergic contact dermatitis</b> ), with extensive skin lesions that persist for at least 3 months despite continuing treatment as prescribed.
<b>Hidradenitis suppurative</b> (108.06)	<b>With extensive lesions</b> involving both axillae, both inguinal areas, or the perineum that persists for at least 3 months despite continuing treatment as prescribed
<b>Genetic photosensitivity disorders</b> (108.07)	Established by clinical and laboratory findings: A. <b>Xeroderma pigmentosum</b> – Consider the individual disabled from birth. B. <b>Other genetic photensitivity disorders, with 1 of the following:</b> 1. Extensive skin lesions lasting or can be expected to last a continuous period of at least 12 months; or 2. Inability to function outside a highly protective environment for a continuous period of at least 12 months.
<b>Burns</b> (108.08)	<b>With extensive skin lesions</b> that have lasted or can be expected to last for a continuous period of at least 12 months.
<b>ENDOCRINE (109.00)</b>	
<b>Thyroid disorders</b> (109.02)	A. <b>Hyperthyroidism</b> , with clinical manifestations despite prescribed therapy, <b>with 1 of the following:</b> 1. Increased <b>serum thyroxine (T4)</b> and either increased free T4 or resin T3 uptake; or 2. Increased <b>thyroid uptake of radioiodine</b> ; or 3. Increased <b>serum triiodothyronine (T<sub>3</sub>)</b> .

<b>Thyroid disorders</b> (109.02) Continued	<b>B. Hypothyroidism</b> , despite prescribed therapy, <b>with 1 of the following:</b> 1. <b>IQ</b> less than or equal to 70; or 2. <b>Growth impairment</b> (100.02); or 3. <b>Precocious puberty</b> .
<b>Hyperparathyroidism</b> (109.03)	<b>With 1 of the following:</b> <b>A.</b> Repeated increased total or ionized <b>serum calcium</b> ; <b>OR</b> <b>B.</b> Increased <b>serum parathyroid hormone</b> .
<b>Hypo- or Pseudohypo-parathyroidism</b> (109.04)	<b>With 1 of the following:</b> <b>A.</b> <b>Severe recurrent tetany or convulsions</b> which are unresponsive to prescribed therapy; <b>OR</b> <b>B.</b> <b>Growth retardation</b> (100.02).
<b>Diabetes insipidus</b> (109.05)	Documented by pathologic hypertonic saline or water deprivation test, <b>and 1 of the following:</b> <b>A.</b> <b>Intracranial space-occupying lesion</b> , before or after surgery; <b>OR</b> <b>B.</b> Unresponsiveness to <b>Pitressin</b> ; <b>OR</b> <b>C.</b> <b>Growth</b> retardation (100.02); <b>OR</b> <b>D.</b> Unresponsive <b>hypothalamic</b> thirst center with chronic or recurrent hypernatremia; <b>OR</b> <b>E.</b> Decreased <b>visual fields</b> attributable to pituitary lesion
<b>Hyperfunction of adrenal cortex</b> (109.06)	<b>Primary or secondary, with BOTH of the following:</b> <b>A.</b> Increased <b>urinary 17 -hydroxycorticosteroids</b> (or 17-ketogenic steroids); <b>AND</b> <b>B.</b> Unresponsiveness to low-dose <b>dexamethasone</b> suppression.
<b>Adrenal cortical insufficiency</b> (109.07)	<b>Adrenal cortical insufficiency</b> with recent, recurrent episodes of circulatory collapse.
<b>Juvenile Diabetes mellitus</b> (109.08)	<b>Requiring parenteral insulin, with 1 of the following</b> , despite prescribed therapy: <b>A.</b> Recent, recurrent <b>hospitalizations with acidosis</b> ; <b>OR</b> <b>B.</b> Recent, recurrent episodes of <b>hypoglycemia</b> ; <b>OR</b> <b>C.</b> <b>Growth retardation (100.02)</b> ; <b>OR</b> <b>D.</b> Impaired <b>renal function (106.00)</b> .
<b>Iatrogenic hypercorticoic state</b> (109.09)	<b>With chronic glucocorticoid therapy resulting in 1 of the following:</b> <b>A.</b> <b>Osteoporosis</b> ; <b>OR</b> <b>B.</b> <b>Growth retardation</b> (100.02); <b>OR</b> <b>C.</b> <b>Diabetes mellitus</b> (109.08); <b>OR</b> <b>D.</b> <b>Myopathy</b> (111.06); <b>OR</b> <b>E.</b> <b>Emotional disorder</b> (112.00).
<b>Pituitary dwarfism</b> (109.10)	<b>With documented growth hormone deficiency and growth impairment</b> (100.02).
<b>Adrenogenital syndrome</b> (109.11)	<b>With 1 of the following:</b> <b>A.</b> Recent, recurrent <b>salt-losing episodes</b> despite prescribed treatment; <b>OR</b> <b>B.</b> Inadequate replacement therapy manifested by <b>accelerated bone age and virilization</b> ; <b>OR</b> <b>C.</b> <b>Growth impairment (100.02)</b> .
<b>Hypoglycemia</b> (109.12)	<b>With recent, recurrent hypoglycemic episodes producing convulsions or coma.</b>
<b>Turner's syndrome</b> (109.13)	<b>(Gonadal Dysgenesis)</b> Chromosomally proven. Evaluate resulting impairment under the criteria for the appropriate body system.

**MULTIPLE BODY SYSTEMS (110.00)**

**Impairments that commonly affect multiple body systems and are significant enough to result in marked & severe functional limitations. In addition to the listings below, many impairments can cause deviation from, or interruption of the normal function of the body or interfere with development (ex: congenital anomalies, chromosomal**

disorders, dysmorphic syndromes, metabolic disorders, & perinatal infections diseases). The functional limitations & the progression of these limitations are more variable than with the catastrophic congenital abnormalities & diseases included in 110.06 – 110.08, so the specific effects on the child are evaluated under the listing criteria in the affected body system(s) and are evaluated on an individual basis. [Examples: Triple X syndrome; Fragile X syndrome; PKU; Caudal Regression Syndrome; Fetal Alcohol Syndrome.]	
<b>Non-mosaic Down syndrome</b> (110.06)	<b>Considered disabled from birth</b> & established by definitive chromosomal analysis (karyotype analysis), or evidence from an acceptable medical source, includes a clinical description of the diagnostic physical features of the impairment & that is persuasive that a positive diagnosis has been confirmed by definitive chromosomal analysis at some time prior to this evaluation. (Report must be consistent with other evidence (ex: showing limitation in adaptive functioning or signs of a mental disorder that can be associated with non-mosaic Down syndrome; educational history; or psychological testing results, etc.)
<b>Mosaic Down syndrome</b> (110.07)	<b>There is a wide range in the level of severity of this impairment – it can be profound and disabling , but it can also be so slight as to be undetected clinically.</b> It is evaluated for disability under the listing criteria in any affected body system(s) on an individual case basis.
<b>Catastrophic congenital abnormality or disease</b> (110.08)	<b>These are present at birth, although they may not be apparent immediately. With 1 of the following:</b> <b>A. Death</b> usually is expected within the 1 <sup>st</sup> months of life, and the <b>rare individuals who survive longer are profoundly impaired</b> (for example, anencephaly, trisomy 13 or 18, cyclopia); <b>OR</b> <b>B. That interferes very seriously with development;</b> for example, cri du chat syndrome (deletion 5p syndrome) or Tay-Sachs disease (acute infantile form).
<b>NEUROLOGICAL (111.00)</b>	
<b>Major motor seizure disorder</b> (111.02)	<b>A. Convulsive epilepsy:</b> More than 1 major motor seizure per month despite 3 months of prescribed treatment, <b>with 1 of the following:</b> 1. <b>Daytime episodes</b> (loss of consciousness and convulsive seizures); or. 2. <b>Night time episodes</b> with residuals interfering with activity during the day.  <b>B. Convulsive epilepsy syndrome: At least 1 major motor seizure in the year prior to application,</b> despite 3 months of prescribed treatment; <b>AND with 1 of the following:</b> 1. <b>IQ</b> less than or equal to 70; or 2. Significant interference with <b>communication</b> due to speech, hearing, or vision defect; or 3. Significant <b>mental disorder</b> ; or 4. Where significant <b>adverse effects of medication</b> interfere with major daily activities.
<b>Nonconvulsive epilepsy</b> (111.03)	<b>Greater than one minor motor seizure per week,</b> with alteration of awareness or loss of consciousness, despite 3 months of prescribed treatment.
<b>Benign brain tumor</b> (111.05)	<b>Evaluate under 111.02, 111.03, 111.06, 111.09 or the criteria of the affected body system.</b>
<b>Motor dysfunction</b> (111.06)	<b>(Due to any neurological disorder)</b> Persistent disorganization or deficit of motor function for age involving 2 extremities, which (despite prescribed therapy) interferes with age-appropriate major daily activities & results in disruption of <b>EITHER</b> fine and gross movements; <b>OR</b> gait and station.
<b>Cerebral palsy</b> (111.07)	<b>With 1 of the following:</b> <b>A. Motor dysfunction</b> (101.02 or 111.06); <b>OR</b> <b>B. Less severe motor dysfunction</b> (but more than slight) <b>and with 1 of the following:</b> 1. <b>IQ</b> less than or equal to 70; or 2. <b>Seizure disorder</b> , with at least one major motor seizure in year prior to application; or 3. Significant interference with <b>communication</b> due to speech, hearing, or vision defect; or 4. Significant <b>emotional disorder</b> .
<b>Meningo-myelocele (&amp; related disorders)</b> (111.08)	<b>With 1 of the following (despite prescribed treatment):</b> <b>A. Motor dysfunction</b> (101.02 or 111.06); <b>OR</b> <b>B. Less severe motor dysfunction</b> (but more than slight) <b>and either</b> urinary/fecal incontinence inappropriate for age; or <b>IQ</b> less than or equal to 70; <b>OR</b> (continued next page)

	<p><b>C. Four extremity involvement; OR</b>  <b>D. Noncompensated hydrocephalus</b> producing interference with mental/motor developmental progression.</p>
<p><b>Communication impairment</b>  (111.09)</p>	<p><b>Associated with documented neurological disorder; and with 1 of following:</b>  <b>A.</b> Documented <b>speech</b> deficit which significantly affects the clarity and content of the speech; OR  <b>B.</b> Documented <b>comprehension</b> deficit resulting in ineffective verbal communication for age; OR  <b>C. Hearing</b> impairment (102.08).</p>
<p><b>MENTAL DISORDERS (112.00)</b></p>	
<p><b>Organic mental disorders</b>  (112.02)</p>	<p><b>Abnormalities in perception, cognition, affect, or behavior associated with brain dysfunction, with Both A and B:</b>  <b>A.</b> Medically documented persistence of <b>1 of following:</b></p> <ol style="list-style-type: none"> <li>1. Developmental arrest, delay, or regression; or</li> <li>2. Disorientation to time and place; or</li> <li>3. Memory impairment, either short-term (inability to learn new information); intermediate, or long-term (inability to remember information that was known in past); or</li> <li>4. Perceptual or thinking disturbance (hallucinations, delusions, illusions, or paranoid thinking); or</li> <li>5. Disturbance in personality (e.g., apathy, hostility); or</li> <li>6. Disturbance in mood (e.g., mania, depression); or</li> <li>7. Emotional lability (e.g., sudden crying); or</li> <li>8. Impairment of impulse control (e.g., disinhibited social behavior, explosive temper outbursts); or</li> <li>9. Impairment of cognitive function (clinically timed standardized psychological testing); or</li> <li>10. Disturbance of concentration, attention, or judgment. <b>AND</b></li> </ol> <p><b>B. (Select appropriate age group):</b></p> <ol style="list-style-type: none"> <li>1. <b>Age 1 to 3 years – with 1 of following:</b> <ol style="list-style-type: none"> <li>a. <b>Gross motor/fine motor</b> development at a level generally acquired by children no more than ½ the child's chronological age; or</li> <li>b. <b>Cognitive/communicative</b> function at a level generally acquired by children no more than ½ the child's chronological age (including medical findings of equivalent abnormality such as inability to use simple verbal/nonverbal behavior to communicate basic needs/concepts); or</li> <li>c. <b>Social function</b> at level generally acquired by children no more than ½ child's chronological age, (including medical findings of an equivalent abnormality exemplified by serious inability to achieve age-appropriate autonomy as manifested by excessive clinging/extreme separation anxiety); or</li> <li>d. <b>Attainment of development/function</b> generally acquired by children no more than 2/3 of child's chronological age in 2 or more areas (GM, FM, cognitive, communicative, or social).</li> </ol> </li> <li>2. <b>Age 3 to 18 years - marked impairment in at least 2 of following:</b> <ol style="list-style-type: none"> <li>a. Age appropriate <b>cognitive/communicative</b> function; or</li> <li>b. Age appropriate <b>social functioning</b>; or</li> <li>c. Age appropriate <b>personal functioning</b>; or</li> <li>d. Marked difficulties in <b>maintaining concentration, persistence, or pace.</b></li> </ol> </li> </ol>
<p><b>Schizophrenic, Delusional (paranoid); Schizoaffective, and other psychotic disorders</b>  (112.03)</p>	<p><b>Onset of psychotic features</b>, characterized by a marked disturbance of thinking, feeling, and behavior, with deterioration from a previous level of functioning or failure to achieve the expected level of social functioning. and <b>with BOTH A AND B:</b>  <b>A. 1 of following</b> (persistence for at least 6 months, either continuous or intermittent):</p> <ol style="list-style-type: none"> <li>1. Delusions or hallucinations; or</li> <li>2. Catatonic, bizarre, or other grossly disorganized behavior; or</li> <li>3. Incoherence, loosening of associations, illogical thinking, or poverty of content of speech; or</li> <li>4. Flat, blunt, or inappropriate affect; or</li> <li>5. Emotional withdrawal, apathy, or isolation. <b>AND</b></li> </ol> <p><b>B. (Select appropriate age group):</b>  <b>Age 1 to 3 years</b> - at least <u>1</u> criteria in B1 of 112.02.  <b>Age 3 to 18 years</b> - at least <u>2</u> criteria in B2 of 112.02.</p>
<p><b>Mood disorders</b>  (112.04)</p>	<p><b>Characterized by a disturbance of mood</b> (referring to a prolonged emotion that colors the whole psychic life, generally involving either depression or elation), <b>accompanied by a full or partial manic or depressive syndrome, with BOTH A AND B:</b> (continued on next page)</p>

<p><b>Mood disorders</b> (112.04) continued</p>	<p><b>A. 1 of following</b> (persisting, either continuous or intermittent):</p> <ol style="list-style-type: none"> <li>1. <b>Major depressive syndrome with at least 5 of following</b> (which must include either depressed or irritable mood or markedly diminished interest or pleasure): <ol style="list-style-type: none"> <li>a. Depressed or irritable mood; or</li> <li>b. Markedly diminished interest or pleasures in almost all activities; or</li> <li>c. Appetite or weight increase or decrease, or failure to make expected weight gains; or</li> <li>d. Sleep disturbance; or</li> <li>e. Psychomotor agitation or retardation; or</li> <li>f. Fatigue or loss of energy; or</li> <li>g. Feelings of worthlessness or guilt; or</li> <li>h. Difficulty thinking or concentrating; or</li> <li>i. Suicidal thoughts or acts; or</li> <li>j. Hallucinations, delusions or paranoid thinking. <b>OR</b></li> </ol> </li> <li>2. <b>Manic syndrome</b> (elevated, expansive or irritable mood), <b>and 3 of following:</b> <ol style="list-style-type: none"> <li>a. Increased activity or psychomotor agitation; or</li> <li>b. Increased talkativeness or pressure of speech; or</li> <li>c. Flight of ideas or subjectively experienced racing thoughts; or</li> <li>d. Inflated self-esteem or grandiosity; or</li> <li>e. Increased need for sleep; or</li> <li>f. Easy distractibility; or</li> <li>g. Involvement in activities with high potential of painful consequences which are not recognized; or</li> <li>h. Hallucinations, delusions/paranoid thinking; <b>OR</b></li> </ol> </li> <li>3. <b>Bipolar or cyclothymic syndrome</b> with history of episodic periods manifested by full symptomatic picture of both manic and depressive syndromes (and currently or most recently characterized by full or partial symptomatic picture of either or both syndromes); <b>AND</b></li> </ol> <p><b>B.</b> (Select appropriate age group):  <b>Age 1 to 3 years</b> - at least 1 criteria in B1 of 112.02.  <b>Age 3 to 18 years</b> - at least 2 criteria in B2 of 112.02.</p>
<p><b>Mental retardation</b> (112.05)</p>	<p><b>Characterized by significantly sub average general intellectual functioning</b> with deficits in adaptive functioning <b>and with 1 of following (A through F):</b></p> <p><b>A.</b> (Select appropriate age group):  <b>Age 1 to 3 years</b> - At least 1 criteria in B1 of 112.02.  <b>Age 3 to 18 years</b> - At least 2 criteria in B2 of 112.02; <b>OR;</b></p> <p><b>B. Mental incapacity</b> - dependence upon others for personal needs (grossly in excess of age appropriate dependence) &amp; inability to follow directions such that use of standardized test is precluded; <b>OR</b></p> <p><b>C. Verbal, performance, or full scale IQ less than or equal to 59; OR</b></p> <p><b>D. Verbal, performance, or full scale IQ of 60 through 70 and a physical or other mental impairment imposing additional and significant limitation of function; OR</b></p> <p><b>E. Verbal, performance, or full scale IQ of 60 through 70, AND</b> (select appropriate group):  <b>Age 1 to 3 years</b> – Attainment of developmental or function generally acquired by children no more than 2/3 of child's chronological age in either gross motor or fine motor (see B1a or B1c of 112.02).  <b>Age 3 to 18 years</b> - Marked impairment in at least one of B2b or B2c or B2d of 112.02; <b>OR</b></p> <p><b>F.</b> (Select appropriate age group):  <b>Age 1 to 3 years</b> - Cognitive/communicative function at 2/3 of child's chronological age in B1b of 112.02 &amp; a physical/other mental impairment imposing an additional &amp; significant functional limitation  <b>3 to 18 years</b> – Meets criteria of social functioning (see 112.02 B2a), and a physical or other mental impairment imposing an additional and significant limitation of function.</p>
<p><b>Anxiety disorders</b> (112.06)</p>	<p><b>either the predominant disturbance or is experienced if the individual attempts to master symptoms</b> ( e.g. confronting the dreaded object or situation in a phobic disorder, attempting to go to school in a separation anxiety disorder, resisting the obsessions or compulsions in an obsessive compulsive disorder, or confronting strangers/peers in avoidant disorders). <b>With BOTH A and B:</b></p> <p><b>A. 1 of following:</b></p> <ol style="list-style-type: none"> <li>1. Excessive anxiety (when child separated/separation is threatened, from parent/parent surrogate; or</li> </ol>

<p><b>Anxiety disorders</b> (112.06)</p> <p>continued</p>	<p>2. Excessive and persistent avoidance of strangers; OR</p> <p>3. Persistent unrealistic or excessive anxiety and worry (apprehensive expectation), accompanied by motor tension, autonomic hyperactivity, or vigilance and scanning; OR</p> <p>4. Persistent irrational fear of specific object, activity or situation resulting in compelling desire to avoid dreaded object, activity or situation; OR [list continued]</p> <p>5. Avg. of once a week recurrent severe panic attacks, manifested by sudden unpredictable onset of intense apprehension, fear or terror, often with a sense of impending doom; OR</p> <p>6. Recurrent and intrusive recollections of traumatic experience, including dreams, which are a sense of marked distress; or</p> <p>7. Recurrent obsessions or compulsions, which are a source of marked distress. <b>AND</b></p> <p><b>B.</b> (Select appropriate age group):  <b>Age 1 to 3 years</b> - at least <u>1</u> criteria in B1 of 112.02.  <b>Age 3 to 18 years</b> - at least <u>2</u> criteria in B2 of 112.02.</p>
<p><b>Somato-form eating &amp; Tic disorders</b> (112.07)</p>	<p><b>Physical symptoms</b> for which there are no demonstrable organic findings or known physiologic mechanisms; <b>or eating and tic disorders with physical manifestations, with BOTH A AND B:</b></p> <p><b>A. 1 of following:</b></p> <p>1. <b>Unrealistic fear and perception of fatness</b> despite being underweight, and persistent refusal to maintain a body weight which is greater than 85% of average weight for height and age; <b>OR</b></p> <p>2. <b>Persistent and recurrent involuntary, repetitive, rapid, purposeless motor movements</b> affecting multiple muscle groups with multiple vocal tics; <b>OR</b></p> <p>3. <b>Persistent nonorganic disturbance of 1 of the following:</b></p> <p>a. Vision; or</p> <p>b. Speech; or</p> <p>c. Hearing; or</p> <p>d. Use of a limb; or</p> <p>e. Movement and its control (coordination disturbance, psychogenic seizures); or</p> <p>f. Sensation (diminished or heightened); or</p> <p>g. Digestion or elimination; or</p> <p>4. <b>Preoccupation with belief that one has serious disease/injury.</b> <b>AND</b></p> <p><b>B.</b> (Select appropriate age group):  <b>Age 1 to 3 years</b> - at least <u>1</u> criteria in B1 of 112.02.  <b>Age 3 to 18 years</b> - at least <u>2</u> criteria in B2 of 112.02.</p>
<p><b>Personality disorders</b> (112.08)</p>	<p><b>Pervasive, inflexible and maladaptive personality traits</b> typical of child's long-term functioning and not limited to discrete episodes of illness, <b>with BOTH A AND B:</b></p> <p><b>A. Deeply ingrained, maladaptive patterns of behavior, associated with 1 of following:</b></p> <p>1. Seclusiveness or autistic thinking; or</p> <p>2. Pathologically inappropriate suspiciousness or hostility; or</p> <p>3. Oddities of thought, perception, speech, and behavior; or</p> <p>4. Persistent disturbances of mood or affect; or</p> <p>5. Pathological dependence, passivity, or aggressiveness; or</p> <p>6. Intense and unstable interpersonal relationships and impulsive and exploitive behavior; or</p> <p>7. Pathological perfectionism and inflexibility. <b>AND</b></p> <p><b>B.</b> (Select appropriate age group):  <b>Age 1 to 3 years</b> - at least 1 of the criteria in B1 of 112.02.  <b>Age 3 to 18 years</b> - at least 2 of the criteria in B2 of 112.02.</p>
<p><b>Psycho-active substance dependence disorders</b> (112.09)</p>	<p><b>Manifested by cluster of cognitive, behavioral, &amp; physiologic symptoms</b> indicating impaired control of psychoactive substance use &amp; continued substance use despite adverse consequences, <b>with BOTH A &amp; B:</b></p> <p><b>A. With 4 of the following:</b></p> <p>1. Substance taken in larger amounts or over a longer period than intended &amp; a great deal of time is spent in recovering from its effects; or</p> <p>2. 2 or more unsuccessful efforts to cut down or control use; or</p> <p>3. Frequent intoxication or withdrawal symptoms interfering with major role obligations; or</p> <p>4. Continued use despite persistent or recurring social, psychological, or physical problems; or</p>

<b>Psycho-active substance dependence disorders</b> (112.09) continued	<p>5. Tolerance, as characterized by requirement for markedly increased amounts of substance in order to achieve intoxication; or</p> <p>6. Substance taken to relieve or avoid withdrawal symptoms; <b>AND</b></p> <p><b>B. (Select appropriate age group):</b>  <b>Age 1 to 3 years</b> – at least 1 of the criteria in B1 of 112.02.  <b>Age 3 to 18 years</b> – at least 2 of the criteria in B2 of 112.02.</p>
<b>Autism and other Pervasive Developmental disorders</b> (112.10)	<p><b>Characterized by qualitative deficits in the development of reciprocal social interaction, verbal &amp; nonverbal communication skills &amp; in imaginative activity.</b> Often, a markedly restricted repertoire of activities and interests, which frequently are stereotyped and repetitive, <b>with BOTH A AND B:</b></p> <p><b>A. For autistic disorders: all of following:</b></p> <ol style="list-style-type: none"> <li>1. Qualitative deficits in development of reciprocal social interaction; and</li> <li>2. Qualitative deficits in verbal and nonverbal communication and in imaginary activity; and</li> <li>3. Markedly restricted repertoire of activities and interests.</li> </ol> <p><b>A. For other pervasive development disorders: both of following:</b></p> <ol style="list-style-type: none"> <li>1. Qualitative deficits in development of reciprocal social interaction; and</li> <li>2. Qualitative deficits in verbal and nonverbal communication and in imaginary activity. <b>AND</b></li> </ol> <p><b>B. (Select appropriate age group):</b>  <b>Age 1 to 3 years</b> - at least 1 of the criteria in B1 of 112.02.  <b>Age 3 to 18 years</b> - at least 2 of the criteria in B2 of 112.02.</p>
<b>ADHD</b> (112.11)	<p>Manifested by developmentally inappropriate degrees of inattention, impulsiveness, &amp; hyperactivity; <b>with BOTH A AND B:</b></p> <p><b>A. All 3 of the following:</b></p> <ol style="list-style-type: none"> <li>1. Marked inattention; and</li> <li>2. Marked impulsiveness; and</li> <li>3. Marked hyperactivity; <b>AND</b></li> </ol> <p><b>B. (Select appropriate age group):</b>  <b>Age 1 to 3 years</b> - at least 1 criteria in 112.02B for this age group.  <b>Age 3 to 18 years</b> - at least 2 criteria in 112.02B for this age group.</p>
<b>Developmental and emotional disorders of newborn and younger infants (Birth to Age 1)</b> (112.12)	<p>May be related to either organic or functional factors or to a combination of these factors; <b>with 1 of following (A thru E):</b></p> <p><b>A. Cognitive/communicative functioning</b> acquired by children no more than ½ of child's chronological age (e.g. in infants 0 to 6 months, markedly variation in the production or imitation of sounds and severe feeding abnormality, such as problems with sucking, swallowing, or chewing); <b>OR</b></p> <p><b>B. Motor development</b> ½ of child's chronological age; <b>OR</b></p> <p><b>C. Apathy, over-excitability, or fearfulness</b>, demonstrated by absent or grossly excessive response to one of the following stimulations: visual; or auditory; or tactile; <b>OR</b></p> <p><b>D. Failure to sustain social interaction on an ongoing, reciprocal basis as evidenced by 1 of following:</b></p> <ol style="list-style-type: none"> <li>1. Inability by 6 months to participate in vocal, visual, and motoric exchanges (including facial expressions); or</li> <li>2. Failure by 9 months to communicate basic emotional responses, such as cuddling or exhibiting protest or anger; or</li> <li>3. Failure to attend to caregiver's voice or face or to explore an inanimate object for period of time appropriate to infant's age; <b>OR</b></li> </ol> <p><b>E. Attainment of development or function</b> generally acquired by children no more than 2/3 of child's chronological age in 2 or more areas (cognitive, communicative, motor, or social).</p>
<b>MALIGNANT NEOPLASTIC DISEASE (113.00)</b>	
<b>Malignant solid tumors</b> (113.03)	<ul style="list-style-type: none"> <li>• <b>Consider a disability for 2 years from time of initial diagnosis.</b> Thereafter, evaluate any residual impairments(s) under the criteria for the affected body system; <b>OR</b></li> <li>• <b>Consider a disability for 2 years from the date of recurrence of active disease.</b> Thereafter, evaluate any residual impairments(s) under the criteria for the affected body system.</li> </ul>

<b>Lymphoma</b> (113.05)	<b>Excluding T-cell lymphoblastic lymphoma; with 1 of the following:</b> <b>A. Non-Hodgkins lymphoma</b> , including Burkitt’s and anaplastic large cell. Persistent or recurrent following initial antineoplastic therapy; <b>OR</b> <b>B. Hodgkin’s disease</b> with failure to achieve clinically complete remission, or recurrent disease within 12 months of completing initial antineoplastic therapy; <b>OR</b> <b>C. Bone marrow or stem cell transplantation</b> (a disability until at least 12 months from date of transplantation. Thereafter, evaluate residual impairment(s) under criteria of affected body system.
<b>Leukemia</b> (113.06)	<b>With 1 of the following:</b> <b>A. Acute leukemia [including T-cell lymphoblastic lymphoma and juvenile chronic myelogenous leukemia (JCML)]</b> (a disability until at least 24 months from the date of diagnosis or relapse, or at least 12 months from the date of bone marrow or stem cell transplantation, whichever is later. Thereafter, evaluate any residual impairments(s) under the criteria for the affected body system); <b>OR</b> <b>B. Chronic myelogenous leukemia (except JCML), with 1 of the following:</b> 1. Accelerated or blast phase. Consider under a disability until at least 24 months from the date of diagnosis or relapse, or at least 12 months from the date of bone marrow or stem cell transplantation, whichever is later. Thereafter, evaluate any residual impairments(s) under the criteria for the affected body system; or 2. Chronic phase, as described in <b>a or b</b> : a. A disability until at least 12 mo. from bone marrow/stem cell transplantation date. Thereafter, evaluate any residual impairment(s) under the criteria for the affected body system; or b. Progressive disease following initial antineoplastic therapy.
<b>Thyroid gland</b> (113.09)	<b>With 1 of the following:</b> <b>A. Anaplastic (undifferentiated) carcinoma; OR</b> <b>B. Carcinoma with metastases</b> beyond regional lymph nodes progressive despite radioactive iodine therapy; <b>OR</b> <b>C. Medullary carcinoma with metastases</b> beyond the regional lymph nodes.
<b>Retino-blastoma</b> (113.12)	<b>With 1 of the following:</b> <b>A. With extension beyond the orbit; OR</b> <b>B. Persistent or recurrent</b> following initial antineoplastic therapy; <b>OR</b> <b>C. With regional or distant metastases.</b>
<b>Brain tumors</b> (113.13)	<b>Highly malignant tumors</b> , such as medulloblastoma or other primitive neuroectodermal tumors (PNETs) with documented metastases, grades III and IV astrocytomas, glioblastoma multiforme, ependymoblastoma, , diffuse intrinsic brain stem gliomas, or primary sarcomas.
<b>Neuro-blastoma</b> (113.21)	<b>With 1 of the following:</b> <b>A. With extension across the midline; OR</b> <b>B. With distant metastasis; OR</b> <b>C. Recurrent; OR</b> <b>D. With onset at age 1 year or older.</b>
<b>IMMUNE SYSTEM (114.00)</b>	
<b>Systemic lupus erythematosus</b> (114.02)	<b>With EITHER A or B:</b> <b>A. Involvement of 2 or more organs/body systems, with BOTH:</b> 1. One of the organs/body systems involved to at least a moderate level of severity; AND 2. At least 2 constitutional symptoms & signs (severe fatigue, fever, malaise, or involuntary weight loss); <b>OR</b> <b>B. Any other manifestation(s) of SLE resulting in one of the following</b> (select appropriate age group): <b>Birth to age 1 year</b> - at least 1of the criteria in 112. 12; or <b>Age 1 to age 3 years</b> - at least 1 of the appropriate age-group criteria in paragraph B1 of 112. 02; or <b>Age 3 to age 18</b> – at least 2 of the appropriate age-group criteria in paragraph B2 of 112.02.
<b>Systemic vasculitis</b> (114.03)	<b>With EITHER A or B:</b> <b>A. Involvement of 2 or more organs/body systems, with BOTH:</b> 1. One of the organs/body systems involved to at least a moderate level of severity; AND 2. At least 2 constitutional symptoms & signs (severe fatigue, fever, malaise, or involuntary weight loss); <b>OR</b> <b>B. Any other manifestation(s) of systems vasculitis resulting in 1 of the following</b> (select appropriate

<b>Systemic Vasculitis,</b> continued	age group): <b>Birth to age 1 year</b> - at least 1of the criteria in paragraphs A-E of 112. 12; or <b>Age 1 to age 3 years</b> - at least 1 of the appropriate age-group criteria in paragraph B1 of 112. 02; or <b>Age 3 to age 18</b> – at least 2 of the appropriate age-group criteria in paragraph B2 of 112.02.
<b>Systemic sclerosis (scleroderma)</b> (114.04)	<b>With 1 of the following:</b> <b>A. Involvement of 2 or more organs/body systems, with both:</b> 1. One of the organs/body systems involved to at least a moderate level of severity; <b>and</b> 2. At least 2 constitutional symptoms & signs (severe fatigue, fever, malaise, or involuntary weight loss); <b>OR</b> <b>B. With 1 of the following:</b> 1. Toe contractures or fixed deformity of 1 or both feet; resulting in the inability to ambulate effectively; or 2. Finger contractures or fixed deformity in both hands, resulting in the inability to perform gross motor and fine motor movements effectively; or 3. Atrophy with irreversible damage in 1 or both lower extremities, resulting in the inability to ambulate effectively; or 4. Atrophy with irreversible damage in both upper extremities, resulting in the inability ro perform fine and gross movements effectively. <b>OR</b> <b>C. Raynaud’s phenomenon, characterized by either:</b> 1. Gangrene involving at least 2 extremities; or 2. Ischemia with ulcerations of toes or fingers, resulting in the inability to ambulate effectively or to perform fine and gross movements effectively; <b>OR</b> <b>D. Any other manifestation(s) of systemic sclerosis (scleroderma) resulting in 1 of the following (select appropriate age group):</b> <b>Birth to age 1 year</b> - at least 1of the criteria in paragraphs A-E of 112.12; or <b>Age 1 to age 3 years</b> - at least 1 of the appropriate age-group criteria in paragraph B1 of 112. 02; or <b>Age 3 to age 18 years</b> – at least 2 of the appropriate age-group criteria in paragraph B2 of 112.02.
<b>Polymyositis &amp; dermatomyositis</b> (114.05)	<b>With 1 of the following:</b> <b>A. Proximal limb-girdle (pelvic or shoulder) muscle weakness,</b> resulting in inability to ambulate effectively or inability to perform fine and gross movements effectively; <b>OR</b> <b>B. Impaired swallowing (dysphagia) with aspiration due to muscle weakness; OR</b> <b>C. Impaired respiration due to intercostal &amp; diaphragmatic muscle weakness; OR</b> <b>D. Diffuse calcinosis with limitation of joint mobility or intestinal motility; OR</b> <b>E. Any other manifestation(s) of polymyositis or dermatomyositis</b> resulting in 1 of the following (select appropriate age group): <b>Birth to age 1 year</b> - at least 1of the criteria in paragraphs A-E of 112.12; or <b>Age 1 to age 3 years</b> - at least 1 of the appropriate age-group criteria in paragraph B1 of 112. 02; or <b>Age 3 to age 18 years</b> – at least 2 of the appropriate age-group criteria in paragraph B2 of 112.02.
<b>Undifferentiated &amp; mixed connective tissue disease</b> (114.06)	<b>With EITHER A or B:</b> <b>A. Involvement of 2 or more organs/body systems, with both</b> 1. One of the organs/body systems involved to at least a moderate level of severity; and 2. At least 2 of the constitutional symptoms and signs (severe fatigue, fever, malaise, or involuntary weight loss); <b>OR</b> <b>B. Any other manifestation(s) of undifferentiated or mixed connective tissue disease</b> resulting in 1 of the following (select appropriate age group): <b>Birth to age 1 year</b> - at least 1of the criteria in paragraphs A-E of 112.12; or <b>Age 1 to age 3 years</b> - at least 1 of the appropriate age-group criteria in paragraph B1 of 112. 02; or <b>Age 3 to age 18 years</b> – at least 2 of the appropriate age-group criteria in paragraph B2 of 112.02
<b>Immune deficiency disorders, excluding HIV</b> (114.07)	<b>With EITHER A, B, or C:</b> <b>A. 1 or more of following infections,</b> resistant to treatment or requiring hospitalization or intravenous treatment 3 or more times in a 12-month period: 1. Sepsis; or 2. Meningitis; or 3. Pneumonia; or

<p><b>Immune deficiency disorders, excluding HIV infection</b> (114.07) (continued)</p>	<p>4. Septic arthritis; or (continued next page ) 5. Endocarditis; or 6. Sinusitis documented by appropriate medically acceptable imaging; <b>OR</b> <b>B. Stem cell transplantation</b> (considered disabled until at least 12 months after the date of transplantation, Thereafter, evaluate any residual impairment(s) under the criteria for the affected body system. <b>OR</b> <b>C. Any other manifestation(s) of an immune deficiency disorder resulting in 1 of the following</b> (select appropriate age group): <b>Birth to age 1 year</b> - at least 1 of the criteria in paragraphs A-E of 112.12; or <b>Age 1 to age 3 years</b> - at least 1 of the appropriate age-group criteria in paragraph B1 of 112. 02; or <b>Age 3 to age 18 years</b> – at least 2 of the appropriate age-group criteria in paragraph B2 of 112.02.</p>
<p><b>HIV</b> (114.08)</p>	<p><b>With 1 of the following (A through O):</b> <b>A. Bacterial Infections: 1 of the following:</b> 1. Mycobacterial infection (e.g. caused y <i>M. avium-intracellulare</i>, <i>M. kansasii</i>, or <i>M. tuberculosis</i>) at site other than the lungs, skin, or cervical or hilar lymph nodes; or pulmonary tuberculosis resistant to treatment; or 2. Nocardiosis; or 3. Salmonella bacteremia, recurrent non-typhoid; or 4. <b>In a child less than 13 yrs old.</b>, multiple or recurrent pyogenic bacterial infections (sepsis, pneumonia, meningitis, bone or joint infection, or abscess of an internal organ or body cavity, but not otitis media or superficial skin or mucosal abscesses) occurring 2 or more times in 2 years. <b>For children age 13 &amp; older</b>, may have an impairment that medically equals this listing if the circumstances of the case warrant (ex: delayed puberty, or they would evaluate pelvic inflammatory disease in older girls) 5. Other multiple or recurrent bacterial infection(s), including pelvic inflammatory disease, requiring hospitalization or intravenous antibiotic treatment 3 or more times in a 12-month period. <b>OR</b> <b>B. Fungal infections: 1 of the following:</b> 1. Aspergillosis; or 2. Candidiasis - involving the esophagus, trachea, bronchi, or lungs, or at a site other than the skin, urinary tract, intestinal tract, or oral or vulvovaginal mucous membranes; or 3. Coccidioidomycosis, at site other than lungs or lymph nodes; or 4. Cryptococcosis, at a site other than lungs (eg, cryptococcal meningitis); or 5. Histoplasmosis, at a site other than lungs or lymph nodes; or 6. Mucorrmycosis; or 7. Pneumocystis pneumonia or extrapulmonary Pneumocystis infection. <b>OR</b> <b>C. Protozoan or helminthic infections: 1 of the following:</b> 1. Cryptosporidiosis, isosporiasis, or microsporidiosis, with diarrhea lasting for 1 month or longer; or 2. Strongyloidiasis, extra-intestinal; or 3. Toxoplasmosis of an organ other than liver, spleen, or lymph nodes. <b>OR</b> <b>D. Viral infections: 1 of the following:</b> 1. Cytomegalovirus disease (CMV) at a site other than the liver, spleen or lymph nodes; or 2. Herpes simplex virus causing 1 of the following: a. Mucocutaneous infection (ex: oral, genital, perianal) lasting 1 month or longer; or b. Infection at site other than skin or mucous membranes (e.g., bronchitis, pneumonitis, esophagitis, or encephalitis); or c. Disseminated infection; or 3. Herpes zoster, either disseminated or with multidermatomal eruptions resistant to treatment; or 4. Progressive multifocal leukoencephalopathy. <b>OR</b> <b>E. Malignant neoplasms: 1 of the following:</b> 1. Carcinoma of cervix, invasive, FIGO stage II and beyond; or 2. Karposi’s sarcoma, with either: extensive oral lesions; or Involvement of the gastrointestinal tract, lungs, or other visceral organs; or 3. Lymphoma (ex: primary lymphoma of the brain, Burkitt's lymphoma, immunoblastic sarcoma, other non-Hodgkin's lymphoma, Hodgkin's disease); or 4. Squamous cell carcinoma of anal canal or anal margin. <b>OR</b> <b>F. Conditions of skin/mucous membranes</b> (other than described in B2, D2, or D3 above), with extensive</p>

<p><b>HIV</b> (114.08) Continued</p>	<p>fungating or ulcerating lesions not responding to treatment (ex: dermatological conditions such as eczema or psoriasis, vulvovaginal or other mucosal Candida, condyloma caused by human papillomavirus, genital ulcerative disease). <b>OR</b></p> <p><b>G. Neurological manifestations of HIV</b> (ex, HIV encephalopathy, peripheral neuropathy) <b>resulting in 1 of the following:</b></p> <ol style="list-style-type: none"> <li>1. Loss of previously acquired, or marked delay in achieving, developmental milestones or intellectual ability (including sudden acquisition of a new learning disability); or</li> <li>2. Impaired brain growth (acquired microcephaly or brain atrophy); or</li> <li>3. Progressive motor dysfunction affecting gait and station or fine and gross motor skills. <b>OR</b></li> </ol> <p><b>H. Growth disturbance, with 1 of the following:</b></p> <ol style="list-style-type: none"> <li>1. Involuntary weight loss (or failure to gain weight at appropriate rate for age), resulting in either a fall of 15 percentiles, or a fall to below the 3rd percentile, that persists for 2 months or longer; or</li> <li>2. Involuntary weight loss of 10 percent or more of baseline (computed based on pounds, kilograms, or body mass index (BMI) that persists for 2 months or longer; <b>OR</b></li> </ol> <p><b>I. Diarrhea, lasting for 1 month or longer</b>, resistant to treatment and requiring intravenous hydration or alimentation, or tube feeding; <b>OR</b></p> <p><b>J. Lymphoid interstitial pneumonia/pulmonary lymphoid hyperplasia (LIP/PLH complex)</b>, with respiratory symptoms that significantly interfere with age-appropriate activities, and that cannot be controlled by prescribed treatment; <b>OR</b></p> <p><b>K. One or more of the following infections</b> (other than described in A-J above), resistant to treatment or require hospitalization or intravenous treatment 3 or more times in a 12-month period: Sepsis; Meningitis; Pneumonia; Septic arthritis; Endocarditis; or Sinusitis documented by appropriate medically acceptable imaging. <b>OR</b></p> <p><b>L. Any other manifestation(s) of HIV infection</b>, including any listed in 114.08 A through K, but without the requisite findings (ex: oral candidiasis not meeting the criteria in 114.08F, diarrhea not meeting the criteria in 114.08I), or any other manifestation(s) (ex: oral hairy leukoplakia, hepatomegaly), resulting in 1 of following (select appropriate age group):</p> <p style="padding-left: 20px;"><b>Birth to 1 year</b>, at least one of the criteria in paragraphs A through E of 112.12; or</p> <p style="padding-left: 20px;"><b>1 year to 3 years</b>, at least one of the age-appropriate age group criteria in paragraph B1 of 112.12; or</p> <p style="padding-left: 20px;"><b>3 years to 18 years</b>, at least 2 of the appropriate age group criteria in paragraph B2 of 112.02.</p>
<p><b>Inflam- matory Arthritis</b> (114.09)</p>	<p><b>With 1 of the following:</b></p> <p><b>A. Persistent inflammation or persistent deformity of either:</b> 1 or more major peripheral weight-bearing joints resulting in the inability to ambulate effectively; <b>or</b> 1 or more peripheral joints in each upper extremity resulting in the inability to perform fine or gross motor movements effectively. <b>OR</b></p> <p><b>B. Inflammation or deformity in 1 or more major peripheral joints with both</b> involvement of 2 or more organs/body systems with 1 of the organs/body systems involved to at least a moderate; and at least 2 constitutional symptoms or signs (severe fatigue, fever, malaise, or involuntary wt. loss). <b>OR</b></p> <p><b>C. Ankylosing spondylitis or other spondyloarthropathy, with</b> ankylosis (fixation) of the dorsolumbar or cervical spine at <b>either</b> 45 degrees or more of flexion measured from the vertical position (zero degrees; <b>or</b> at 30 degrees or more of flexion (but less than 45 degrees) and involvement of 2 or more organs/body systems involved to at least a moderate level of severity. <b>OR</b></p> <p><b>D. Any other manifestation(s) of inflammatory arthritis</b> resulting in (select appropriate age group):</p> <p style="padding-left: 20px;"><b>Birth to 1 year</b>, at least one of the criteria in paragraphs A through E of 112.12; or</p> <p style="padding-left: 20px;"><b>1 year to 3 years</b>, at least one of the age-appropriate age group criteria in paragraph B1 of 112.12; or</p> <p style="padding-left: 20px;"><b>3 years to 18 years</b>, at least 2 of the appropriate age group criteria in paragraph B2 of 112.02.</p>
<p><b>Sjogren's syndrome</b> (114.10)</p>	<p><b>With EITHER A or B:</b></p> <p><b>A. Involvement of 2 or more organs/body systems with both</b> 1 of the organs/body systems involved to at least a moderate level of severity; <b>and</b> at least 2 of the constitutional symptoms &amp; signs (severe fatigue, fever, malaise, or involuntary weight loss: <b>OR</b></p> <p><b>B. Any other manifestation(s) of Sjogren's syndrome resulting in</b> (select appropriate age group):</p> <p style="padding-left: 20px;"><b>Birth to 1 year</b>, at least one of the criteria in paragraphs A through E of 112.12; or</p> <p style="padding-left: 20px;"><b>1 year to 3 years</b>, at least one of the age-appropriate age group criteria in paragraph B1 of 112.12; or</p> <p style="padding-left: 20px;"><b>3 years to 18 years</b>, at least 2 of the appropriate age group criteria in paragraph B2 of 112.02.</p>